Examples of using Yondelis in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
What is Yondelis?
Yondelis contains potassium.
Other information about Yondelis.
What Yondelis contains.
To prevent vomiting and to protect the liver, an infusion of dexamethasone(a corticosteroid) should be given before each Yondelis dose.
Yondelis replacements and reviews.
You will be given a medicine before and as needed during the treatment with Yondelis in order to protect your liver and to reduce the risk of side effects such as feeling sick(nausea) and vomiting.
Yondelis with alcohol.
In patients receiving it once every three weeks, it took an average of 3.8 months for their disease to get worse,compared with 2.1 months in those receiving Yondelis three times per month.
Yondelis® has so far been approved for the treatment of soft tissue sarcomas- rare, malignant connective-tissue tumours.
Studies including patients with severe renal insufficiency(creatinine clearance< 30 ml/ min)have not been conducted and therefore Yondelis must not be used in this patient population see section 4.4.
Yondelis must be given under the supervision of a doctor who is experienced in the use of chemotherapy medicines to treat cancer.
Unless otherwise specified, the following safety profile of Yondelis is based on the evaluation in clinical trials of patients treated with the recommended treatment regimens for both indications.
Yondelis may also be tested against other tumour types such as breast cancer, which kills 130 000 EU citizens a year, and with other treatments.
You should have received training on the correct techniques to reconstitute and dilute Yondelis and you should wear protective clothing including mask, goggles and gloves during the reconstitution and dilution.
Yondelis in combination with pegylated liposomal doxorubicin(PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer.
If you are given a medicine that might cause damage tothe liver or to the muscles(rhabdomyolysis), you may need to be closely monitored when using Yondelis together with this medicine, as there could be an increased risk of damage.
Yondelis 0.25 mg powder for concentrate for solution for infusion Yondelis 1 mg powder for concentrate for solution for infusion Trabectedin.
Studies including patients with renal insufficiency(creatinine clearance< 30 ml/min for the monotherapy, and< 60 ml/min for the combination regimen)have not been conducted and therefore Yondelis must not be used in this patient population see section 4.4.
The active substance in Yondelis, trabectedin, is a synthetic version of a substance that was originally extracted from a species of tunicate or‘sea squirt' a marine animal.
Yondelis in combination with pegylated liposomal doxorubicin(PLD: another anti-cancer medicine) is used for the treatment of patients with ovarian cancer that has come back after at least 1 previous therapy and are not resistant to anti-cancer medicines containing platinum compounds.
For soft-tissue sarcoma, the recommended dose of Yondelis is 1.5 mg per square metre of body surface area(calculated using the patient's height and weight), given as a single infusion lasting 24 hours every three weeks.
The recommended dose of Yondelis is 1.5 mg per square metre of body surface(calculated using the patient' s height and weight), given as a single intravenous infusion(drip into a vein) over 24 hours every three weeks.
The company that makes Yondelis will continue to assess which patients are more likely to respond to the medicine, and will carry out a study to investigate the effects of Yondelis in patients with a type of cancer called‘ myxoid liposarcoma.
For ovarian cancer, the combination of Yondelis and PLD was more effective than PLD alone: patients receiving the combination treatment lived for an average of 7.3 months without their disease getting worse, compared with 5.8 months in those receiving PLD alone.
For soft-tissue sarcoma, Yondelis has been studied in one main study involving 266 patients with liposarcoma(a sarcoma originating in fat cells) or leiomyosarcoma(a sarcoma originating in‘smooth' or involuntary muscle cells) that was advanced or metastatic had spread to other parts of the body.
Unless otherwise specified, the following safety profile of Yondelis is based on the evaluation in clinical trials of 569 patients treated up to April 2007 with the recommended treatment regime in several cancer types including soft tissue sarcoma, breast cancer, osteosarcoma, ovarian cancer, GIST, melanoma and renal carcinoma.
If you use other medicines,you may need to be closely monitored as the effects of Yondelis might be decreased(examples are medicines containing rifampicin(for bacterial infections), phenobarbital(for epilepsy) or St. John's Wort(Hypericum perforatum, herbal medicine for depression)) or increased(examples are medicines containing ketoconazole or fluconazole(for fungal infections), ritonavir(for HIV infection), clarithromycin(for bacterial infections), ciclosporin(inhibit the defensive system of the body) or verapamil(for high blood pressure and heart conditions)) as a result.